Physician profile
Sandy A Jackson
NPI 1043671530
$9,927.12
in general payments reported to CMS, 2019-2025
38 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $918 · 2022: $2,427 · 2023: $2,547 · 2024: $2,432 · 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,498 · Education: $83.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,498.03 |
| Education | $83.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,543.57 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,422.95 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,059.76 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $972.58 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $824.77 | 2021-2025 | |
| Amgen INC. | $558.31 | 2021-2025 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $405.06 | 2021-2025 | Gardasil 9, Gardasil, Vaxneuvance |
| Bayer Healthcare Pharmaceuticals INC. | $358.75 | 2022-2025 | |
| Pfizer INC. | $285.95 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $283.13 | 2022-2024 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.94 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lundbeck LLC | $204.62 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $181.10 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $172.19 | 2021-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $167.72 | 2022-2025 | Rexulti, Abilify Maintena |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.